Search research articles
Contact Us
Filters
Showing results (231-240 of 493) with videos related to
Page
of 50
Sort By:
Journal for Immunotherapy of Cancer
|
January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma
Hollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
Journal of Translational Medicine
|
July 31, 2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
Antoni Ribas, John M Kirkwood, Michael B Atkins, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 27, 2002
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer
Paula G Fraenkel, Seward B Rutkove, Jean K Matheson, et al.
JAMA Oncology
|
March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Naomi B Haas, Judith Manola, Janice P Dutcher, et al.
Clinical Genitourinary Cancer
|
May 13, 2021
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study
Michael Szarek, Michael N Needle, Brian I Rini, et al.
The Oncologist
|
February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
Miguel Zugman, David F McDermott, Bernard J Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
Keith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
Cancer Medicine
|
October 11, 2017
High frequency of brain metastases after adjuvant therapy for high-risk melanoma
Wolfram E Samlowski, James Moon, Merle Witter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2000
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma
D F McDermott, J W Mier, D P Lawrence, et al.
Cell
|
April 10, 2007
The mammalian Golgi regulates numb signaling in asymmetric cell division by releasing ACBD3 during mitosis
Yan Zhou, Joshua B Atkins, Santiago B Rompani, et al.
Page
of 50
Search research articles
Search
Showing results (231-240 of 493) with videos related to
Sort By:
Page
of 50
Journal for Immunotherapy of Cancer
|
January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma
Hollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
Journal of Translational Medicine
|
July 31, 2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
Antoni Ribas, John M Kirkwood, Michael B Atkins, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 27, 2002
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer
Paula G Fraenkel, Seward B Rutkove, Jean K Matheson, et al.
JAMA Oncology
|
March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Naomi B Haas, Judith Manola, Janice P Dutcher, et al.
Clinical Genitourinary Cancer
|
May 13, 2021
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study
Michael Szarek, Michael N Needle, Brian I Rini, et al.
The Oncologist
|
February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
Miguel Zugman, David F McDermott, Bernard J Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
Keith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
Cancer Medicine
|
October 11, 2017
High frequency of brain metastases after adjuvant therapy for high-risk melanoma
Wolfram E Samlowski, James Moon, Merle Witter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2000
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma
D F McDermott, J W Mier, D P Lawrence, et al.
Cell
|
April 10, 2007
The mammalian Golgi regulates numb signaling in asymmetric cell division by releasing ACBD3 during mitosis
Yan Zhou, Joshua B Atkins, Santiago B Rompani, et al.
Page
of 50